key: cord-0704410-962r8w9r
authors: Pavri, Behzad B.; Kloo, Juergen; Farzad, Darius; Riley, Joshua M.
title: Behavior of the PR Interval with Increasing Heart Rate in Patients with COVID-19
date: 2020-06-11
journal: Heart Rhythm
DOI: 10.1016/j.hrthm.2020.06.009
sha: 19f9039c81e737506795ec6e6d12a9b34cf2e4c5
doc_id: 704410
cord_uid: 962r8w9r

BACKGROUND: Myriad manifestations of cardiovascular involvement are described in Coronavirus disease 2019 (COVID-19) but there have been no reports of COVID-19 affecting the cardiac conduction system. The PR interval on the electrocardiogram (ECG) normally shortens with increasing heart rate (HR). We encountered a COVID-19 patient manifesting Mobitz 1 atrioventricular (AV) block which normalized as he improved, prompting us to investigate PR interval behavior in COVID-19. OBJECTIVES: To characterize PR interval behavior in hospitalized COVID-19 patients, and correlate with clinical outcomes. METHODS: This study was a cross-sectional cohort analysis of confirmed COVID-19 cases (March 26–April 25, 2020). We reviewed pre-COVID-19 and COVID-19 ECGs to characterize AV conduction by calculating the PR interval to HR (PR:HR) slope. Clinical endpoints were death or need for endotracheal intubation. RESULTS: ECGs from 75 patients (246 pre-COVID-19 ECGs and 246 COVID-19 ECGs) were analyzed for PR:HR slope. Of these, 38 patients (50.7%) showed the expected PR interval shortening with increasing HR (negative PR:HR slopes), whereas 37 patients (49.3%) showed either no change (8 with PR:HR slopes=0) or paradoxical PR interval prolongation (29 with positive PR:HR slopes) with increasing HR. Patients without PR interval shortening were more likely to die (11/37, 29.7% vs. 3/38, 7.9%, P=0.019) or require endotracheal intubation (16/37, 43.2% vs. 8/38, 21.1%, P=0.05) compared to patients with PR interval shortening. CONCLUSION: Half of COVID-19 patients showed abnormal PR interval behavior (paradoxical prolongation or lack of shortening) with increasing HR. This finding was associated with increased risk of death and need for endotracheal intubation.

In health, the PR interval shows predictable and consistent non-linear shortening as heart rate 65 (HR) accelerates; this is true whether the increase in HR is achieved by exercise or by 66 sympathomimetic drugs.(7) This physiologic adaptation preserves atrioventricular (AV) 67 synchrony and maintains optimal ventricular filling during HR acceleration. Epidemiologic 68 studies have confirmed this inverse correlation of PR interval and HR, and this relationship 69 remains reproducible over time. (8, 9, 10) 70 We noted that many COVID-19 patients showed abnormal PR interval behavior. This 71 observation was first noticed in a 63 year-old man with COVID-19 without prior cardiac disease 72 whose admitting electrocardiogram (ECG) showed 2 nd degree, Mobitz were analyzed per patient. The pre-COVID-19 ECGs were obtained during previous illness 91 requiring hospitalization. All ECGs were visually scanned, and PR intervals were re-measured 92 with electronic calipers when HRs were >100 bpm or when there were obvious errors in 93 computer-generated measurements. For manual measurements, we used the "superimposed 94 median" format at twice paper speed and twice gain, as shown in Figure 1 . This format is a 95 nonlinear digital filtering technique used to remove noise by replacing each digital data point of 96 the ECG tracing with the median of neighboring data points (11). This allowed precise 97 measurements to be made even with rapid HRs and baseline artifact. PR interval 98 measurements were recorded separately from outcomes data and laboratory values. and reported as percentages. When a laboratory value was not found in the patient's 120 electronic health record, it was assumed that the test had not been performed. Table 2 . 143 The average length of hospital stay was 11.7±0.7 (range 3 -28) days; the median length of stay (Table 3) . All other laboratory test values were not significantly 148 different between the two groups, although a trend toward higher peak hs-troponin-T levels 149 was noted (P=0.053). Limitations: Our study has limitations including those inherent to retrospective analyses of 198 observational data. Less than 25% of screened patients met inclusion criteria primarily because 199 we had to limit our analysis to patients with at least two ECGs in order to calculate PR:HR 200 slopes. Although this strict inclusion criterion may have selected a sicker baseline patient 201 population, the availability of prior ECGS allowed each patient to serve as their own control. 202 These inclusion criteria were applied to all patients, and possible selection bias does not explain 203 the differences in PR interval behavior seen during COVID-19 as compared to prior illnesses. PR 204 measurements can be error-prone, but we used the superimposed median format at twice 205 magnification and twice paper speed along with electronic calipers to minimize such errors. 206 Another limitation relates to the time span over which ECGs were acquired; the pre-COVID-19 207 ECGs were obtained over a longer period of time (mean 3.5 years), as compared to COVID ECGs 208 obtained during the index hospitalization (mean 5.5 days). Accordingly, the COVID PR:HR 209 slopes was selected as the dichotomizing variable rather than the slope difference over time. 

COVID-19 and the cardiovascular system

Clinical features of patients infected with 2019 novel 230 coronavirus in Wuhan, China

Segment Elevation in Patients with Covid

Clinical characteristics of coronavirus disease 2019 in China

Clinical 255 determinants of the PR interval duration in Swiss middle-aged adults: The CoLaus/PsyCoLaus 256 study

PR interval behavior during exercise 258 stress test

Fever and Cardiac Rhythm

Prognostic significance of fever-induced Brugada 262 syndrome

Jones Criteria (modified) for guidance in the 264 diagnosis of rheumatic fever: report of the committee on standards and criteria for programs of 265 care

Rheumatic fever

Cardiac conduction system affection in a case of 268 swine flu

Coagulopathy and Antiphospholipid Antibodies in 273 Patients with Covid-19

Lupus Anticoagulant and Abnormal Coagulation 275 Tests in Patients with Covid-19

Antiphospholipid antibodies, antiphospholipid syndrome 278 and viral infections

Antibodies to Ribonucleoprotein, and Congenital Heart Block